Trial site
Tucson
Tucson, Arizona 85704, United StatesNot linked to an institution yet
- 12running trials
- 6closed trials
The trials here
What the 18 trials at this site are about, from their registry records.
- Phase
- Phase 310 trials
- Phase 23 trials
- Phase 12 trials
- Phase 2/31 trial
- Phase 41 trial
- Status
- Active, not recruiting7 trials
- Completed5 trials
- Recruiting5 trials
- Withdrawn1 trial
- Lead sponsor
- GlaxoSmithKline14 trials
- Tesaro, Inc.4 trials
Running trials
Recruiting
A Study to Investigate Abdominal Symptoms With Camlipixant Compared With Placebo in Adults With Irritable Bowel Syndrome - Diarrhea (IBS-D) and Irritable Bowel Syndrome - Mixed (IBS-M)
NCT07519395· Phase 2· GlaxoSmithKline· Source
Contact: Bassel Kisso (principal investigator)
Recruiting
A Pivotal Clinical Study to Investigate Efimosfermin Alfa in Participants With Biopsy-confirmed F2- or F3-stage MASH
NCT07221227· Phase 3· GlaxoSmithKline· Source
Contact: Hani Rizk (principal investigator)
Recruiting
A Study of Efimosfermin Alfa in Participants With Biopsy-confirmed Cirrhosis (Compensated) Due to MASH
NCT06920043· Phase 2· GlaxoSmithKline· Source
Contact: Aimee Bachelier (principal investigator)
Active, not recruiting
A Study Describing the Efficacy and Safety of Belimumab Administered in Adult Participants With Early Systemic Lupus Erythematosus (SLE)
NCT06411249· Phase 4· GlaxoSmithKline· Source
Recruiting
A Study of the Efficacy and Safety of Belimumab in Adults With Systemic Sclerosis Associated Interstitial Lung Disease
NCT05878717· Phase 2/3· GlaxoSmithKline· Source
Contact: Sachin Chaudhary (principal investigator)
Recruiting
Study of Perioperative Dostarlimab in Participants With Untreated T4N0 or Stage III dMMR/MSI-H Resectable Colon Cancer
NCT05855200· Phase 3· GlaxoSmithKline· Source
Contact: Manuel Modiano (principal investigator)
Active, not recruiting
Belantamab Mafodotin Plus Pomalidomide and Dexamethasone (Pd) Versus Bortezomib Plus Pd in Relapsed/Refractory Multiple Myeloma
NCT04484623· Phase 3· GlaxoSmithKline· Source
Active, not recruiting
Study of Single Agent Belantamab Mafodotin Versus Pomalidomide Plus Low-dose Dexamethasone (Pom/Dex) in Participants With Relapsed/Refractory Multiple Myeloma (RRMM)
NCT04162210· Phase 3· GlaxoSmithKline· Source
Active, not recruiting
A Study to Evaluate Dostarlimab Plus Carboplatin-paclitaxel Versus Placebo Plus Carboplatin-paclitaxel in Participants With Recurrent or Primary Advanced Endometrial Cancer
NCT03981796· Phase 3· Tesaro, Inc.· Source
Active, not recruiting
A Comparison of Platinum-based Therapy With TSR-042 and Niraparib Versus Standard of Care (SOC) Platinum-based Therapy as First-line Treatment of Stage III or IV Nonmucinous Epithelial Ovarian Cancer
NCT03602859· Phase 3· Tesaro, Inc.· Source
Active, not recruiting
A Study of Niraparib (GSK3985771) Maintenance Treatment in Participants With Advanced Ovarian Cancer Following Response on Front-Line Platinum-Based Chemotherapy
NCT02655016· Phase 3· Tesaro, Inc.· Source
Active, not recruiting
A Study of TSR-022 in Participants With Advanced Solid Tumors (AMBER)
NCT02817633· Phase 1· Tesaro, Inc.· Source
Recruiting at the same time
How many trials recruit for the same indication here at once. A count, not a rating.
Report an error